Dazadrol

Dazadrol

Clinical data
Other names	Sch 12650
Identifiers
IUPAC name (4-chlorophenyl)-(4,5-dihydro-1H-imidazol-2-yl)-pyridin-2-ylmethanol
CAS Number	47029-84-5 25387-70-6
PubChem CID	32940
ChemSpider	30497
UNII	9U27285V5R
ChEMBL	ChEMBL2110607
CompTox Dashboard (EPA)	DTXSID60866124
ECHA InfoCard	100.051.158
Chemical and physical data
Formula	C15H14ClN3O
Molar mass	287.75 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN=C(N1)C(C2=CC=C(C=C2)Cl)(C3=CC=CC=N3)O
InChI InChI=1S/C15H14ClN3O/c16-12-6-4-11(5-7-12)15(20,14-18-9-10-19-14)13-3-1-2-8-17-13/h1-8,20H,9-10H2,(H,18,19) Key:DITYEPYMBCHKLF-UHFFFAOYSA-N

Dazadrol is a synthetic antidepressant developed by Schering Corp in the late 1960s. It acts primarily as a noradrenaline reuptake inhibitor, increasing concentrations of noradrenaline in the synaptic cleft, which is believed to underlie its antidepressant effects. ^{[1] [2] [3]}

Dazadrol is classified as a pyridinemethanol derivative and has been studied for its impact on neurological function and mood. In addition to its antidepressant activity, preclinical studies in rats have shown that it inhibits both basal and induced gastric acid secretion, indicating potential gastrointestinal effects. ^{[1] [3] [4] [2]}

See also

• Mazindol
• Trazium
• AW-15'1129

References

1. "Dazadrol". Inxight Drugs. The National Center for Advancing Translational Sciences (NCATS).
2. Lippmann W (May 1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2-[p-chlorophenyl-2-(pyridyl)hydroxymethyl] imidazoline maleate (Sch-12650)". The Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x. PMID   4393004.
3. Schmitt H, Petillot N (1971). "[Pharmacological properties of a new potential antidepressant: ((p-chlorophenyl)-2-(pyridyl)-hydroxymethyl) imidazoline (SCH 12.650)]". Therapie (in French). 26 (4): 805–821. PMID   5119131.
4. Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN   978-0-412-46630-4.